Atovaquone
Atovaquone is a topic covered in the Johns Hopkins HIV Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Prevention of Pneumocystis jirovecii pneumonia in patients who are intolerant to TMP/SMX
- Oral treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (second or third line)
- Prevention and treatment of malaria (in combination with proguanil: see separate module)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Toxoplasmosis treatment alone (limited data with atovaquone 750 mg four times a day in adults)
- Toxoplasmosis treatment in combination with pyrimethamine or sulfadiazine
- Babesiosis (in combination with azithromycin)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Prevention of Pneumocystis jirovecii pneumonia in patients who are intolerant to TMP/SMX
- Oral treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (second or third line)
- Prevention and treatment of malaria (in combination with proguanil: see separate module)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Toxoplasmosis treatment alone (limited data with atovaquone 750 mg four times a day in adults)
- Toxoplasmosis treatment in combination with pyrimethamine or sulfadiazine
- Babesiosis (in combination with azithromycin)
There's more to see -- the rest of this entry is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved